The Company is a Korea-based company principally engaged in the development, manufacture and distribution of antibody drug. The Company developed a bio synergy antibody, a therapeutic antibody for a new mechanism that is different from conventional therapeutic agents, and is based on the YPLUS and AffiMab platforms. The company s products include AC101, AC103, AC104, AC106, AC203, AM201, AM101, AM102 and AM103. The Company distributes its products within domestic market and to overseas markets. The Company was established on June 25, 2010. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on September 18, 2017.
Headquarters
1401, 285, Digital-Ro, Guro-Gu
Seoul; Seoul;
Contact Details: Purchase the Abclon Inc. report to view the information.
Website: http://www.abclon.co.kr
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service